Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Schmitz

Showing results (311-320 of 385) with videos related to

Pageof 39
Sort By:
Early Intervention in Psychiatry|January 18, 2023
Predictors of treatment attrition of cognitive health interventions in first episode psychosisChristy Au-Yeung, Christopher R Bowie, Tina Montreuil, et al.
British Journal of Haematology|December 30, 2014
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre studySebastian Kirschey, Thomas Flohr, Hans H Wolf, et al.
Hemasphere|March 21, 2024
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort studyPhilipp Berning, Evgenii Shumilov, Markus Maulhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysisJohannes Schetelig, Anja van Biezen, Ronald Brand, et al.
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
British Journal of Haematology|October 10, 2017
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patientsMichael Pfreundschuh, Niels Murawski, Samira Zeynalova, et al.
Haematologica|December 11, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcomeStephen P Robinson, Anna Sureda, Carmen Canals, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphomaAndreas Josting, Horst Müller, Peter Borchmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 studyMarkus Schaich, Christoph Röllig, Silke Soucek, et al.
Pageof 39

Showing results (311-320 of 385) with videos related to

Sort By:
Pageof 39
Early Intervention in Psychiatry|January 18, 2023
Predictors of treatment attrition of cognitive health interventions in first episode psychosisChristy Au-Yeung, Christopher R Bowie, Tina Montreuil, et al.
British Journal of Haematology|December 30, 2014
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre studySebastian Kirschey, Thomas Flohr, Hans H Wolf, et al.
Hemasphere|March 21, 2024
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort studyPhilipp Berning, Evgenii Shumilov, Markus Maulhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysisJohannes Schetelig, Anja van Biezen, Ronald Brand, et al.
Blood Advances|May 13, 2020
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORALSarit Assouline, Shen Li, Christian Gisselbrecht, et al.
British Journal of Haematology|October 10, 2017
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patientsMichael Pfreundschuh, Niels Murawski, Samira Zeynalova, et al.
Haematologica|December 11, 2008
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcomeStephen P Robinson, Anna Sureda, Carmen Canals, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphomaAndreas Josting, Horst Müller, Peter Borchmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 studyMarkus Schaich, Christoph Röllig, Silke Soucek, et al.
Pageof 39